«

»

May 30

Advaxis commences enrollment in ADXS-HPV Phase 1/2 study for mind and neck cancer Advaxis.

HPV is connected with 40-70 percent of head and throat cancers. This trial is being conducted at the Aintree Hospital at the University of Liverpool, the Royal Marsden Medical center at the University of London, and the Cardiff Hospital at the University of Wales. The analysis will investigate the protection and efficacy of the novel immunotherapeutic agent in preventing recurrence of head and neck cancer among patients who’ve been treated with surgery, radiotherapy, and/or chemotherapy; alone or in combination.So imagine a common language for MRI reports or operative notes. Although market influence is indisputable, such an explanation conflicts with the impression I got from Judy Faulkner, chief executive officer of EHR maker Epic Systems, who advocates for government-created standards. Whether or not other vendors are willing to make their products interoperable, government often overrides industry’s financial passions to achieve a larger public good. I’m all for those who have vision problems.